Pharmarise Holdings (2796) · FactDropped
Recording COVID-19 Infection-Control Costs
First written in FY2021-Q3. 1 of 7 entries say "Dropped", first in FY2024. Latest entry: FY2024.
7entries
4years
0from disclosures
How it moved
Same theme, other companies
Extraordinary Losses for COVID-19 Infection-Prevention MeasuresA theme 5 companies write about · 5 as a headwind · 0 as a tailwind
0 other companies' latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2024DroppedAnnual report
「Because the amount was no longer material, it is included in “Other” for the fiscal year.」
COVID-19 infection-control expenses were no longer presented separately and were moved to “Other” because their materiality had declined. - FY2023Elimination of infection-control expensesAnnual report
「COVID-19 infection-control expenses 21 0」
COVID-19 infection-control expenses declined from ¥21 million in the previous year to ¥0 million in the current year. - FY2022Decrease in infection-control expensesAnnual report
「COVID-19 infection-control expenses 280 21」
COVID-19 infection-control expenses declined from ¥280 million in the previous year to ¥21 million. - FY2022-Q3Cumulative decrease in infection-control expensesAnnual report
「COVID-19 infection-control expenses 197 20」
COVID-19 infection-control expenses for the first nine months of the fiscal year were ¥20 million, down from ¥197 million in the same period of the previous year. - FY2022-Q2Decrease in infection-control expensesAnnual report
「COVID-19 infection-control expenses 5」
COVID-19 infection-control expenses were ¥5 million, down from ¥22 million in the same period of the previous year. - FY2021Increase in infection-control expensesAnnual report
「COVID-19 infection-control expenses 280」
¥280 million in COVID-19 infection-control expenses was recognized as a non-operating expense. - FY2021-Q3First statedAnnual report
「Ordinary profit declined 18.1% year on year, mainly due to the recognition of ¥197 million in COVID-19 infection-control expenses and other factors.」
For the first time, the Company separately identified the recognition of ¥197 million in COVID-19 infection-control expenses as an extraordinary factor behind the decline in ordinary profit.